DURECT Reports Data From European Phase IIb Shoulder Study of Posidur) (SABER-Bupivacaine) and Amendment of the Nycomed Agreement - Drugs.com MedNews
Links shared publicly online about this topic.
- 516total visits
DURECT Reports Data From European Phase IIb Shoulder Study of Posidur) (SABER-Bupivacaine) and Amendment of the Nycomed Agreement - Drugs.com MedNews
DURECT Corporation (Nasdaq DRRX) announced today results from a European Phase IIb shoulder clinical trial conducted by Nycomed of POSIDUR (also known as SABER
View full resource at drugs.com
Tags: Drug, Clinical Trial, Nycomed
Most Recently Shared on February 10, 2011 at 11:22 pm By:
DURECT Reports Data From European Phase IIb Shoulder Study of Posidur) (SABER-Bupivacaine) and Amendment o... http://bit.ly/fdbrvW #drug
Advertisement
